Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.67 |
| ▸ | DRD2 | P14416 | 3/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | LIPE | Q05469 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9302891 | 0.85 | HTR1A (0.54) | HTR1ADRD2GAAMAPTTDP1 | |
| SCHEMBL6830502 | 0.85 | DRD2 (0.50) | HTR1ADRD2GAAMAPTTDP1 | |
| SCHEMBL23881745 | 0.85 | HTR1A (0.73) | HTR1ADRD2GAAMAPTTDP1 | |
| SCHEMBL13986127 | 0.84 | HTR1A (0.53) | HTR1ADRD2GAAMAPTTDP1 | |
| SCHEMBL15583063 | 0.83 | HTR1A (0.51) | HTR1ADRD2GAAMAPTTDP1 | |
| SCHEMBL10601013 | 0.82 | DRD2 (0.69) | HTR1ADRD2GAAMAPTTDP1 | |
| SCHEMBL3457914 | 0.81 | PTPRC (0.54) | HTR1ADRD2ALDH1A1ABCB1 | |
| SCHEMBL25173265 | 0.81 | ABCB1 (0.57) | HTR1ADRD2MAPTTDP1L3MBTL1 | |
| SCHEMBL31351920 | 0.81 | DRD2 (0.53) | HTR1ADRD2HPGDABCB1 | |
| SCHEMBL30758619 | 0.80 | CCR5 (0.56) | LMNAALDH1A1PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101279899-A | Preparation of phenol 2-[2-(3-methoxyphenyl) ethyl] | UNIV CHINA PHARMA (CN) | 2008-10-08 | — | — | CN | claimed |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | AVILAR THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| WO-2024182772-A2 | MANNOSE 6-PHOSPHATE RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| CN-109535155-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20210346369-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2021-11-11 | — | — | US | disclosed |
| US-20200345717-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2020-11-05 | — | — | US | disclosed |
| CN-109661387-A | For treating the composition of pulmonary fibrosis | 维克图斯生物系统有限公司 | 2019-04-19 | — | — | CN | disclosed |
| EP-2768830-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20180221363-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-08-09 | — | — | US | disclosed |
| EP-0958293-A1 | NANOMOLAR, NON-PEPTIDE INHIBITORS OF CATHEPSIN D | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-11-24 | — | — | EP | disclosed |
| US-5834468-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, ANALGESICS TREATING RHEUMATIC DISEASE, BONE DISORDER, INJURIES | ZENECA LIMITED (GB) | 1998-11-10 | — | — | US | disclosed |
| US-5811459-A | PAIN RELIEVERS | ZENECA LIMITED (GB) | 1998-09-22 | — | — | US | disclosed |
| WO-1998033795-A1 | NANOMOLAR, NON-PEPTIDE INHIBITORS OF CATHEPSIN D | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-08-06 | — | — | WO | disclosed |
| EP-0752421-A1 | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists | ZENECA LIMITED (GB) | 1997-01-08 | — | — | EP | disclosed |
| EP-0733033-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996011902-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-04-25 | — | — | WO | disclosed |
| US-5331006-A | Cholecystokinin, antisecretory agents | WARNER-LAMBERT COMPANY (US) | 1994-07-19 | — | — | US | disclosed |
| EP-0487270-A2 | HIV protease inhibitors having polyether substituents | MERCK & CO. INC. (US) | 1992-05-27 | — | — | EP | disclosed |
| WO-1992004025-A1 | AMINO ACID ANALOGS AS CCK ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345717-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | HTR1A 4777/4885DRD2 4799/4885GAA 2491/4885 |
| US-20210346369-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | HTR1A 4777/4885DRD2 4799/4885GAA 2491/4885 |
| US-20180221363-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | HTR1A 4777/4885DRD2 4799/4885GAA 2491/4885 |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | IGF2R, M6PR, MSR1 | HTR1A 1878/4885DRD2 3317/4885GAA 1965/4885 |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | HTR1A 4144/4885DRD2 4539/4885GAA 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.